medigraphic.com

2012, Number 5

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (5)

Hepatitis C virus infection and type 2 diabetes mellitus in Mexican patients

Chiquete E, Ochoa-Guzmán A, García-Lamas L, Anaya-Gómez F, Gutiérrez-Manjarrez JI, Sánchez-Orozco LV, Godínez-Gutiérrez SA, Maldonado M, Román S, Panduro A

Language: English
References: 30
Page: 481-486
PDF size: 127.58 Kb.


ABSTRACT

Objective: to measure the frequency of type 2 diabetes mellitus (T2DM) in patients with confirmed HCV infection.
Methods: we studied 125 adults reactive to anti-HCV antibodies (62.4 % women, mean age 46.8 years) who received confirmatory RT-PCR testing for viremia (63.2 % HCV-RNA-positive).
Results: twenty-two patients had T2DM (17.6 %, 95 % confidence interval: 11.8-25.3 %; mean National prevalence: 14.4 %), more frequent among patients with detectable viremia than in negative cases (23.3 % vs. 9.6 %, respectively; p = 0.04), and among those with advanced liver disease, than in compensated patients (28.9 % vs. 11.3 %, respectively; p = 0.01). Fourteen (17.7 %) patients received interferon-based treatment and 6 (42.8 %) had sustained virology response. None of the 6 responders had T2DM, but 2 of the 8 (25 %) non-responders had diabetes. T2DM patients were older than those without diabetes (57.7 vs. 44.5 years, p ‹ 0.001), and after multivariate analysis, only age was significantly associated with diagnosis of T2DM.
Conclusions: T2DM was highly prevalent among patients with chronic HCV infection. Age was the most important determining factor.



REFERENCES

  1. Sistema Nacional de Información en Salud. [Website]. Statistics on general mortality. SINAIS; Mexico: 2008. Accesed on August 24, 2011. Available at http://sinais. salud.gob.mx/

  2. Chiquete E, Nuño-González P, Panduro A. Perspectiva histórica de la diabetes mellitus: comprendiendo la enfermedad. Investigación en Salud 2001;III(marzo):5-10.

  3. Osler W. The principles and practice of medicine. New York: Appleton; 1942.

  4. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30(3):734-743.

  5. Tellez-Ávila FI, Sánchez-Ávila F, García-Sáenz-de-Sicilia M, Chávez-Tapia NC, Franco-Guzmán AM, López-Arce G, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008;14(30):4771-4775.

  6. Kobashi-Margáin RA, Gutiérrez-Grobe Y, Ponciano-Rodríguez G, Uribe M, Méndez-Sánchez N. Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico. Ann Hepatol 2010;9(3):282-288.

  7. Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int 2010;30(3):356-364.

  8. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21(6):1135-1139.

  9. Fraser GM, Harman I, Meller N, Niv Y, Porath A. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996;32(7):526-530.

  10. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999;29(2):328-333.

  11. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with endstage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 2000;32(2):209-217.

  12. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133(8):592-599.

  13. Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis 2003;36(10):1318- 1323.

  14. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003;38(1):50-56.

  15. Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury. Diabetes Care 2004;27(5):1171-1175.

  16. Wilson C. Hepatitis C infection and type 2 diabetes in American- Indian women. Diabetes Care 2004;27(9):2116-2119.

  17. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral näive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect 2005;50(4):331-337.

  18. Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol 2007;102(6):1237-1243.

  19. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int 2008;28(3):355-362.

  20. Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G. Chisholm Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010;138(3):932-41.e1-3.

  21. Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care 2005; 28(4):940-941.

  22. Villalpando S, de la Cruz V, Rojas R, Shamah-Levy T, Ávila MA, Gaona B, et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Publica Mex 2010;52(Suppl 1):S19-S26.

  23. Chiquete E, Sánchez LV, Becerra G, Quintero A, Maldonado M, Panduro A. Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican transfusion center. Ann Hepatol 2005;4(4):275-278.

  24. Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: a systematic review. Intervirology 2007;50(1):1-8.

  25. Chiquete E, Sánchez LV, Maldonado M, Quezada D, Panduro A. Prediction of the hepatitis C viremia using immunoassay data and clinical expertise. Ann Hepatol 2005;4(2):107- 114.

  26. Rivas-Estilla AM, Sánchez LV, Matsui O, Campollo O, Armendáriz-Borunda J, Segura-Ortega JE, et al. Identification of hepatitis C virus (HCV) genotypes in infected patients from the west of Mexico. Hepatol Res 1998;12 (2):121-130.

  27. Chiquete E, Sánchez LV, Panduro A. Routes of infection and clinical outcome of Mexican women reactive to anti-hepatitis C virus antibodies. Hepatol Res 2006;36(2)100-106.

  28. Simó R, Lecube A, Genescà J, Esteban JI, Hernández C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006;29(11):2462-2466.

  29. Knobler H, Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad. QJM 2005;98(1):1-6.

  30. Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009;15(13):1537-1547.




2020     |     www.medigraphic.com